Loading organizations...
Loading organizations...

Automating clinical trials, starting with patient recruitment.
Phases has raised $500K across 1 funding round.
Key people at Phases.
Phases was founded in 2025 by Anton Zaliznyi (Co-founder & Chief AI Officer) and James Wall (Co-founder & CEO) and Jonathan van Wersch (Co-founder & CTO).
Phases has raised $500K in total across 1 funding round.
Phases uses AI to automate clinical trial operations, starting with patient recruitment. Our agent scans medical records and conducts human-like voice interviews to assess patient eligibility for clinical trials. Our vision is to run the entire clinical trial back-office with agents, getting drugs to market at a fraction of the time and cost it takes today.
Phases is a company automating clinical trials with a focus on patient recruitment, leveraging AI and digital tools to streamline and personalize the process. Its mission is to accelerate clinical trial enrollment by reducing friction in patient matching, screening, and engagement, thereby improving trial efficiency and outcomes. The company builds AI-powered platforms that serve clinical trial sponsors, research sites, and patients by automating eligibility checks, personalized communication, and retention strategies. This solves the critical problem of recruitment delays, which cause most trial extensions and budget overruns, by making recruitment faster, more accurate, and patient-centric. Phases is gaining growth momentum by integrating advanced AI-driven trial matching, multilingual outreach, and decentralized trial support, positioning itself as a key innovator in clinical trial automation.
For an investment firm interested in Phases, the company fits within sectors such as healthtech, AI in healthcare, and clinical research innovation. Its impact on the startup ecosystem includes pushing forward data-driven, patient-focused clinical trial solutions that reduce costly delays and improve trial diversity and accessibility.
Phases was founded by experts in clinical research and AI technology who recognized the persistent bottleneck in clinical trial patient recruitment. The idea emerged from observing how traditional recruitment methods—relying on physician referrals and patient self-discovery—were inefficient and exclusionary. Early traction came from deploying AI-powered tools that automate eligibility screening using electronic health records (EHR) and dynamic questionnaires, significantly reducing screen failure rates and speeding enrollment. Pivotal moments included successful pilot programs demonstrating improved patient retention through AI-driven engagement tools like chatbots and personalized reminders.
Phases rides the wave of digital transformation in clinical trials, driven by increasing demand for faster, more cost-effective drug development and the rise of decentralized clinical trials (DCTs). The timing is critical as regulatory agencies and sponsors push for more inclusive, patient-centric trials, and as AI and real-world data become mainstream in healthcare. Market forces such as rising trial complexity, diversity requirements, and patient engagement challenges favor AI-enabled recruitment solutions. By improving recruitment speed and accuracy, Phases influences the broader ecosystem by enabling more efficient trial designs, reducing failure rates, and promoting equitable access to clinical research.
Looking ahead, Phases is poised to expand its AI capabilities, incorporating predictive analytics and smarter protocol simulations to further reduce trial failures before enrollment begins. Trends shaping its journey include growing adoption of decentralized trials, increased regulatory support for digital tools, and the integration of genomics and other biomarker data into recruitment algorithms. Its influence may evolve from a recruitment enabler to a comprehensive clinical trial automation platform, driving innovation across trial design, patient engagement, and data management. This positions Phases as a critical player in transforming how clinical trials are conducted, ultimately accelerating the path from research to patient benefit.
Key people at Phases.
Phases was founded in 2025 by Anton Zaliznyi (Co-founder & Chief AI Officer) and James Wall (Co-founder & CEO) and Jonathan van Wersch (Co-founder & CTO).
Phases has raised $500K in total across 1 funding round.
Phases's investors include Antler, Brand Foundry Ventures, Conviction Partners, Jenny Fielding, Scott Hartley, IrishAngels, Motivate Ventures, Pelion Venture Partners, Rev1 Ventures, Scale Asia Ventures, Uncork Capital, Y Combinator.
Phases has raised $500K across 1 funding round. Most recently, it raised $500K Seed in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $500K Seed | Antler, Brand Foundry Ventures, Conviction Partners, Jenny Fielding, Scott Hartley, IrishAngels, Motivate Ventures, Pelion Venture Partners, Rev1 Ventures, Scale Asia Ventures, Uncork Capital, Y Combinator, Chris Smoak, Tom Blomfield |